menu
    • menu

    Company profile for TRexBio

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We believe breakthrough therapeutics for patients with inflammatory diseases are within reach. By targeting the underlying dysregulation that drives disease, our team is identifying and advancing a pipeline of medicines that have the potential to transform how we treat debilitating inflammatory conditions.We are decoding human tissue biology to create revolutionary therapeutics.We are a team of experienced and passionate scien...
    We believe breakthrough therapeutics for patients with inflammatory diseases are within reach. By targeting the underlying dysregulation that drives disease, our team is identifying and advancing a pipeline of medicines that have the potential to transform how we treat debilitating inflammatory conditions.We are decoding human tissue biology to create revolutionary therapeutics.We are a team of experienced and passionate scientists, drug development experts, and industry leaders. We are committed to decoding the human tissue immune system and believe we are uniquely positioned to usher in breakthrough medicines with this approach.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TRexBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    681 Gateway Blvd, 4th Floor, SSF 94080
    Telephone
    Telephone
    650-567-5582
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://trex.bio/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/trexbio-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Trexbio Secures $50M Funding For Advancing Tissue-Targeted Treg
    Trexbio Secures $50M Funding For Advancing Tissue-Targeted Treg

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127311389/en/TRexBio-Closes-%2450-Million-Financing-to-Support-a-Growing-Clinical-Stage-Immunology-Pipeline-of-Tissue-Targeted-Treg-Therapeutics

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    TrexBio to Present at Investor Conferences in Sept Conference
    TrexBio to Present at Investor Conferences in Sept Conference

    03 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-03/trexbio-to-participate-in-upcoming-investor-conferences-in-september

    PHARMAWEB
    03 Sep 2025
    Share Share
    TRexBio Doses First Participant in Phase 1 Trial of TRB-061
    TRexBio Doses First Participant in Phase 1 Trial of TRB-061

    03 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250521505737/en/TRexBio-Doses-First-Participant-in-Phase-1-Trial-of-TRB-061-a-Novel-TNFR2-Agonist-for-Atopic-Dermatitis-and-Other-Inflammatory-Diseases

    BUSINESSWIRE
    03 Jun 2025
    Share Share
    TRexBio appoints Ariella Kelman as CMO and Brandon Hants as CFO
    TRexBio appoints Ariella Kelman as CMO and Brandon Hants as CFO

    08 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250408390088/en/TRexBio-Expands-Leadership-Team-with-Appointments-of-Ariella-Kelman-M.D.-as-Chief-Medical-Officer-and-Brandon-Hants-MBA-as-Chief-Financial-Officer

    BUSINESSWIRE
    08 Apr 2025
    Share Share
    TRexBio Secures $84M to Advance Immunology Pipeline
    TRexBio Secures $84M to Advance Immunology Pipeline

    13 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241113888699/en

    BUSINESSWIRE
    13 Nov 2024
    Share Share
    TRexBio Announces Lilly Has Initiated Phase 1 Study for Autoimmune Diseases
    TRexBio Announces Lilly Has Initiated Phase 1 Study for Autoimmune Diseases

    26 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240625989975/en

    BUSINESSWIRE
    26 Jun 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search